SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Medicinska grundvetenskaper) hsv:(Medicinsk genetik) "

Sökning: hsv:(MEDICIN OCH HÄLSOVETENSKAP) hsv:(Medicinska grundvetenskaper) hsv:(Medicinsk genetik)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Deshpande, J, et al. (författare)
  • Ultrastructural changes in the hippocampal CA1 region following transient cerebral ischemia: evidence against programmed cell death.
  • 1992
  • Ingår i: Experimental brain research. Experimentelle Hirnforschung. Expérimentation cérébrale. - 0014-4819. ; 88:1, s. 91-105
  • Tidskriftsartikel (refereegranskat)abstract
    • The ultrastructural changes in the pyramidal neurons of the CA1 region of the hippocampus were studied 6 h, 24 h, 48 h, and 72 h following a transient 10 min period of cerebral ischemia induced by common carotid occlusion combined with hypotension. The pyramidal neurons showed delayed neuronal death (DND), i.e. at 24 h and 48 h postischemia few structural alterations were noted in the light microscope, while at 72 h extensive neuronal degeneration was apparent. The most prominent early ultrastructural changes were polysome disaggregation, and the appearance of electron-dense fluffy dark material associated with tubular saccules. Mitochondria and nuclear elements appeared intact until frank neuronal degeneration. The dark material accumulated with extended periods of recirculation in soma and in the main trunks of proximal dendrites, often beneath the plasma membrane, less frequently in the distal dendrites and seldom in spines. Protein synthesis inhibitors (anisomycin, cycloheximide) and an RNA synthesis inhibitor (actinomycin D), administered by intrahippocampal injections or subcutanously, did not mitigate neuronal damage. Therefore, DND is probably not apoptosis or a form of programmed cell death. We propose that the dark material accumulating in the postischemic period represents protein complexes, possibly aggregates of proteins or internalized plasma membrane fragments, which may disrupt vital cellular structure and functions, leading to cell death.
  •  
2.
  • Mondal, Tanmoy, et al. (författare)
  • Sense-antisense lncRNA pair encoded by locus 6p22.3 determines neuroblastoma susceptibility via the USP36-CHD7-SOX9 regulatory axis
  • 2018
  • Ingår i: Cancer Cell. - 1535-6108. ; 33:3, s. 417-434.e7
  • Tidskriftsartikel (refereegranskat)abstract
    • Trait-associated loci often map to genomic regions encoding long noncoding RNAs (lncRNAs), but the role of these lncRNAs in disease etiology is largely unexplored. We show that a pair of sense/antisense lncRNA (6p22lncRNAs) encoded by CASC15 and NBAT1 located at the neuroblastoma (NB) risk-associated 6p22.3 locus are tumor suppressors and show reduced expression in high-risk NBs. Loss of functional synergy between 6p22lncRNAs results in an undifferentiated state that is maintained by a gene-regulatory network, including SOX9 located on 17q, a region frequently gained in NB. 6p22lncRNAs regulate SOX9 expression by controlling CHD7 stability via modulating the cellular localization of USP36, encoded by another 17q gene. This regulatory nexus between 6p22.3 and 17q regions may lead to potential NB treatment strategies. Mondal et al. show a sense/antisense lncRNA pair expressed from the neuroblastoma (NB) risk-associated 6p22.3 locus is important for retinoic acid-induced NB differentiation gene-regulatory network by controlling CHD7 stability via modulating the cellular localization of the ubiquitin specific protease USP36.
  •  
3.
  •  
4.
  • Munthe, Christian, 1962-, et al. (författare)
  • The Return of Lombroso? Ethical Aspects of (Visions of) Preventive Forensic Screening
  • 2015
  • Ingår i: Public Health Ethics. - 1754-9973 .- 1754-9981. ; 8:3, s. 270-283
  • Tidskriftsartikel (refereegranskat)abstract
    • The vision of legendary criminologist Cesare Lombroso to use scientific theories of individual causes of crime as a basis for screening and prevention programmes targeting individuals at risk for future criminal behaviour has resurfaced, following advances in genetics, neuroscience and psychiatric epidemiology. This article analyses this idea and maps its ethical implications from a public health ethical standpoint. Twenty-seven variants of the new Lombrosian vision of forensic screening and prevention are distinguished, and some scientific and technical limitations are noted. Some lures, biases and structural factors, making the application of the Lombrosian idea likely in spite of weak evidence are pointed out and noted as a specific type of ethical aspect. Many classic and complex ethical challenges for health screening programmes are shown to apply to the identified variants and the choice between them, albeit with peculiar and often provoking variations. These variations are shown to actualize an underlying theoretical conundrum in need of further study, pertaining to the relationship between public health ethics and the ethics and values of criminal law policy.
5.
  • Eklund, Erik, et al. (författare)
  • Proteoglycan production in disomic and trisomy 7-carrying human synovial cells.
  • 2002
  • Ingår i: Matrix Biology. - Elsevier. - 1569-1802. ; 21:4, s. 325-335
  • Tidskriftsartikel (refereegranskat)abstract
    • To gain further insight into the synthesis and structure of the synovial matrix of joints, we have established cell cultures from synovial specimens and elaborated their production of hyaluronan and proteoglycans. The cultures secreted mainly the small proteoglycan decorin, but also considerable amounts of the related biglycan and the large proteoglycan versican. Only minor amounts of heparan sulfate proteoglycans were found. All cultures also had a high production of hyaluronan, which highlights the important role for normal joint function of these cells. In joint diseases, a common feature is the presence of an extra chromosome 7 (trisomy 7) in the synovial cells. To study the possible consequences of trisomy 7 on the synovial cell function, we extended our study to cultures that had been sub-cloned to contain high amounts of trisomy 7-carrying cells. These cell cultures had approximately four times more versican than their disomic counterparts in the cell culture medium, indicating that versican may be a mediator in the processes of joint destructive disorders. To find an explanation for this increase in versican, we investigated the expression/secretion of PDGF-AA and IL-6, cytokines with their genes located to chromosome 7. Indeed, both these cytokines were increased in the cultures with high frequencies of trisomy 7. We then added the two cytokines to cell cultures of disomic synovial cells, but only cells treated with IL-6 displayed an increased amount of versican. Thus, we suggest that the increased amount of versican in cultures of trisomy 7-carrying cells relates to an autocrine loop involving an increased IL-6 production.
  •  
6.
  • Björn, Niclas, et al. (författare)
  • Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia
  • 2020
  • Ingår i: The Pharmacogenomics Journal. - Nature Publishing Group. - 1470-269X .- 1473-1150. ; 20:2, s. 179-191
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Chemotherapy-induced myelosuppression, including thrombocytopenia, is a recurrent problem during cancer treatments that may require dose alterations or cessations that could affect the antitumor effect of the treatment. To identify genetic markers associated with treatment-induced thrombocytopenia, we whole-exome sequenced 215 non-small cell lung cancer patients homogeneously treated with gemcitabine/carboplatin. The decrease in platelets (defined as nadir/baseline) was used to assess treatment-induced thrombocytopenia. Association between germline genetic variants and thrombocytopenia was analyzed at single-nucleotide variant (SNV) (based on the optimal false discovery rate, the severity of predicted consequence, and effect), gene, and pathway levels. These analyses identified 130 SNVs/INDELs and 25 genes associated with thrombocytopenia (<em>P</em>-value &lt; 0.002). Twenty-three SNVs were validated in an independent genome-wide association study (GWAS). The top associations include rs34491125 in <em>JMJD1C</em> (<em>P</em>-value = 9.07 × 10<sup>−5</sup>), the validated variants rs10491684 in <em>DOCK8</em> (<em>P</em>-value = 1.95 × 10<sup>−4</sup>), rs6118 in <em>SERPINA5</em> (<em>P</em>-value = 5.83 × 10<sup>−4</sup>), and rs5877 in <em>SERPINC1</em> (<em>P</em>-value = 1.07 × 10<sup>−3</sup>), and the genes <em>CAPZA2</em> (<em>P</em>-value = 4.03 × 10<sup>−4</sup>) and <em>SERPINC1</em> (<em>P</em>-value = 1.55 × 10<sup>−3</sup>). The SNVs in the top-scoring pathway <em>“Factors involved in megakaryocyte development and platelet production”</em> (<em>P</em>-value = 3.34 × 10<sup>−4</sup>) were used to construct weighted genetic risk score (wGRS) and logistic regression models that predict thrombocytopenia. The wGRS predict which patients are at high or low toxicity risk levels, for CTCAE (odds ratio (OR) = 22.35, <em>P</em>-value = 1.55 × 10<sup>−8</sup>), and decrease (OR = 66.82, <em>P</em>-value = 5.92 × 10<sup>−9</sup>). The logistic regression models predict CTCAE grades 3–4 (receiver operator characteristics (ROC) area under the curve (AUC) = 0.79), and large decrease (ROC AUC = 0.86). We identified and validated genetic variations within hematopoiesis-related pathways that provide a solid foundation for future studies using genetic markers for predicting chemotherapy-induced thrombocytopenia and personalizing treatments.</p>
  •  
7.
  • Björn, Niclas, 1990- (författare)
  • Pharmacogenetic biomarkers for chemotherapy-induced adverse drug reactions
  • 2019
  • Doktorsavhandling (övrigt vetenskapligt)abstract
    • <p>Cancer is a serious disease expected to be the world-leading cause of death in the 21st century. The use of harsh chemotherapies is motivated and accepted but, unfortunately, is often accompanied by severe toxicity and adverse drug reactions (ADRs). These occur because the classical chemotherapies’ common modes of action effectively kill and/or reduce the growth rate not only of tumour cells, but also of many other rapidly dividing healthy cells in the body. There are also considerable interindividual differences in ADRs, even between patients with similar cancers and disease stage treated with equal doses; some experience severe to life-threatening ADRs after one dose, leading to treatment delays, adjustments, or even discontinuation resulting in suboptimal treatment, while others remain unaffected through all treatment cycles. Being able to predict which patients are at high or low risk of ADRs, and to adjust doses accordingly before treatment, would probably decrease toxicity and patient suffering while also increasing treatment tolerability and effects. In this thesis, we have used next-generation sequencing (NGS) and bioinformatics for the prediction of myelosuppressive ADRs in lung and ovarian cancer patients treated with gemcitabine/carboplatin and paclitaxel/carboplatin.</p><p>Paper I shows that <em>ABCB1 </em>and <em>CYP2C8 </em>genotypes have small effects inadequate for stratification of paclitaxel/carboplatin toxicity. This supports the transition to whole-exome sequencing (WES) and whole-genome sequencing (WGS). Papers II and IV, respectively, use WES and WGS, and demonstrate that genetic variation in or around genes involved in blood cell regulation and proliferation, or genes differentially expressed at chemotherapy exposure, can be used in polygenic prediction models for stratification of gemcitabine/carboplatininduced myelosuppression. Paper III reassuringly shows that WES and WGS are concordant and mostly yield comparable genotypes across the exome. Paper V proves that single-cell RNA sequencing of hematopoietic stem cells is a feasible method for elucidating differential transcriptional effects induced as a response to <em>in vitro </em>chemotherapy treatment.</p><p>In conclusion, our results supports the transition to genome-wide approaches using WES, WGS, and RNA sequencing to establish polygenic models that combine effects of multiple pharmacogenetic biomarkers for predicting chemotherapy-induced ADRs. This approach could be applied to improve risk stratification and our understanding of toxicity and ADRs related to other drugs and diseases. We hope that our myelosuppression prediction models can be refined and validated to facilitate personalized treatments, leading to increased patient wellbeing and quality of life.</p>
  •  
8.
  • Deming, Y., et al. (författare)
  • The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk
  • 2019
  • Ingår i: Science Translational Medicine. - 1946-6234. ; 11:505
  • Tidskriftsartikel (refereegranskat)abstract
    • Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cerebrospinal fluid (CSF) has been associated with Alzheimer's disease (AD). TREM2 plays a critical role in microglial activation, survival, and phagocytosis; however, the pathophysiological role of sTREM2 in AD is not well understood. Understanding the role of sTREM2 in AD may reveal new pathological mechanisms and lead to the identification of therapeutic targets. We performed a genome-wide association study (GWAS) to identify genetic modifiers of CSF sTREM2 obtained from the Alzheimer's Disease Neuroimaging Initiative. Common variants in the membrane-spanning 4-domains subfamily A (MS4A) gene region were associated with CSF sTREM2 concentrations (rs1582763; P = 1.15 × 10-15); this was replicated in independent datasets. The variants associated with increased CSF sTREM2 concentrations were associated with reduced AD risk and delayed age at onset of disease. The single-nucleotide polymorphism rs1582763 modified expression of the MS4A4A and MS4A6A genes in multiple tissues, suggesting that one or both of these genes are important for modulating sTREM2 production. Using human macrophages as a proxy for microglia, we found that MS4A4A and TREM2 colocalized on lipid rafts at the plasma membrane, that sTREM2 increased with MS4A4A overexpression, and that silencing of MS4A4A reduced sTREM2 production. These genetic, molecular, and cellular findings suggest that MS4A4A modulates sTREM2. These findings also provide a mechanistic explanation for the original GWAS signal in the MS4A locus for AD risk and indicate that TREM2 may be involved in AD pathogenesis not only in TREM2 risk-variant carriers but also in those with sporadic disease.
  •  
9.
  • Fischer, M Dominik, et al. (författare)
  • Expression profiling reveals metabolic and structural components of extraocular muscles
  • 2002
  • Ingår i: Physiological Genomics. - American Physiological Society. - 1094-8341 .- 1531-2267. ; 9:2, s. 71-84
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>The extraocular muscles (EOM) are anatomically and physiologically distinct from other skeletal muscles. EOM are preferentially affected in mitochondrial myopathies, but spared in Duchenne's muscular dystrophy. The anatomical and pathophysiological properties of EOM have been attributed to their unique molecular makeup: an allotype. We used expression profiling to define molecular features of the EOM allotype. We found 346 differentially expressed genes in rat EOM compared with tibialis anterior, based on a twofold difference cutoff. Genes required for efficient, fatigue-resistant, oxidative metabolism were increased in EOM, whereas genes for glycogen metabolism were decreased. EOM also showed increased expression of genes related to structural components of EOM such as vessels, nerves, mitochondria, and neuromuscular junctions. Additionally, genes related to specialized functional roles of EOM such as the embryonic and EOM-specific myosin heavy chains and genes for muscle growth, development, and/or regeneration were increased. The EOM expression profile was validated using biochemical, structural, and molecular methods. Characterization of the EOM expression profile begins to define gene transcription patterns associated with the unique anatomical, metabolic, and pathophysiological properties of EOM.</p>
  •  
10.
  • Guerreiro, R., et al. (författare)
  • Investigating the genetic architecture of dementia with Lewy bodies : a two-stage genome-wide association study
  • 2018
  • Ingår i: The Lancet Neurology. - Lancet Ltd. - 1474-4422. ; 17:1, s. 64-74
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Dementia with Lewy bodies is the second most common form of dementia in elderly people but has been overshadowed in the research field, partly because of similarities between dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. So far, to our knowledge, no large-scale genetic study of dementia with Lewy bodies has been done. To better understand the genetic basis of dementia with Lewy bodies, we have done a genome-wide association study with the aim of identifying genetic risk factors for this disorder. Methods In this two-stage genome-wide association study, we collected samples from white participants of European ancestry who had been diagnosed with dementia with Lewy bodies according to established clinical or pathological criteria. In the discovery stage (with the case cohort recruited from 22 centres in ten countries and the controls derived from two publicly available database of Genotypes and Phenotypes studies [phs000404.v1.p1 and phs000982.v1.p1] in the USA), we performed genotyping and exploited the recently established Haplotype Reference Consortium panel as the basis for imputation. Pathological samples were ascertained following autopsy in each individual brain bank, whereas clinical samples were collected after participant examination. There was no specific timeframe for collection of samples. We did association analyses in all participants with dementia with Lewy bodies, and also only in participants with pathological diagnosis. In the replication stage, we performed genotyping of significant and suggestive results from the discovery stage. Lastly, we did a meta-analysis of both stages under a fixed-effects model and used logistic regression to test for association in each stage. Findings This study included 1743 patients with dementia with Lewy bodies (1324 with pathological diagnosis) and 4454 controls (1216 patients with dementia with Lewy bodies vs 3791 controls in the discovery stage; 527 vs 663 in the replication stage). Results confirm previously reported associations: APOE (rs429358; odds ratio [OR] 2·40, 95% CI 2·14–2·70; p=1·05 × 10−48), SNCA (rs7681440; OR 0·73, 0·66–0·81; p=6·39 × 10−10), an GBA (rs35749011; OR 2·55, 1·88–3·46; p=1·78 × 10−9). They also provide some evidence for a novel candidate locus, namely CNTN1 (rs7314908; OR 1·51, 1·27–1·79; p=2·32 × 10−6); further replication will be important. Additionally, we estimate the heritable component of dementia with Lewy bodies to be about 36%. Interpretation Despite the small sample size for a genome-wide association study, and acknowledging the potential biases from ascertaining samples from multiple locations, we present the most comprehensive and well powered genetic study in dementia with Lewy bodies so far. These data show that common genetic variability has a role in the disease. Funding The Alzheimer's Society and the Lewy Body Society.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (965)
Typ av publikation
tidskriftsartikel (2755)
doktorsavhandling (255)
forskningsöversikt (90)
konferensbidrag (88)
bokkapitel (67)
annan publikation (47)
visa fler...
bok (7)
recension (7)
samlingsverk (redaktörskap) (4)
licentiatavhandling (3)
visa färre...
Typ av innehåll
refereegranskat (2863)
övrigt vetenskapligt (597)
populärvet., debatt m.m. (2)
Författare/redaktör
Vihinen, Mauno, (166)
Mertens, Fredrik, (148)
Johansson, Bertil, (99)
Melander, Olle, (96)
Mitelman, Felix, (91)
Mandahl, Nils, (87)
visa fler...
Groop, Leif, (86)
Franks, Paul W, (82)
Fioretos, Thoas, (78)
Lind, Lars, (75)
Gisselsson Nord, Dav ... (73)
Uitterlinden, Andre ... (72)
Ingelsson, Erik (65)
Hayward, Caroline (63)
Gudnason, Vilmundur (60)
McCarthy, Mark I (60)
Langenberg, Claudia (60)
Salomaa, Veikko (60)
Esko, Tonu (60)
Hofman, Albert (59)
Metspalu, Andres (59)
Loos, Ruth J. F. (59)
Kristoffersson, Ulf, (59)
Rotter, Jerome I. (58)
Hemminki, Kari, (57)
Morris, Andrew P. (57)
Boerwinkle, Eric (57)
Stefansson, Kari (56)
Höglund, Mattias, (55)
Harris, Tamara B. (55)
Mahajan, Anubha (55)
Psaty, Bruce M. (53)
Scott, Robert A (53)
Luan, Jian'an (53)
Orho-Melander, Marju ... (52)
Chasman, Daniel I., (52)
Munthe, Christian, 1 ... (52)
Wareham, Nicholas J (51)
Panagopoulos, Ioanni ... (51)
Boehnke, Michael (50)
Gieger, Christian (50)
Borg, Åke, (50)
Lindgren, Cecilia M. (50)
Van Duijn, Cornelia ... (49)
Samani, Nilesh J. (49)
Deloukas, Panos (48)
Laakso, Markku, (48)
Teumer, Alexander (46)
Mohlke, Karen L (46)
Peters, Annette (46)
visa färre...
Lärosäte
Lunds universitet (1573)
Uppsala universitet (651)
Göteborgs universitet (459)
Karolinska Institutet (448)
Umeå universitet (304)
Linköpings universitet (94)
visa fler...
Örebro universitet (75)
Chalmers tekniska högskola (62)
Stockholms universitet (48)
Kungliga Tekniska Högskolan (30)
Sveriges Lantbruksuniversitet (17)
Högskolan i Jönköping (14)
Högskolan i Skövde (13)
Högskolan Dalarna (9)
swepub_uni:mau_t (5)
Mittuniversitetet (5)
Gymnastik- och idrottshögskolan (5)
Högskolan Kristianstad (3)
Linnéuniversitetet (3)
Högskolan i Borås (2)
Högskolan i Halmstad (1)
VTI - Statens väg- och transportforskningsinstitut (1)
visa färre...
Språk
Engelska (3208)
Svenska (46)
Odefinierat språk (1)
Spanska (1)
Polska (1)
Rumänska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (3322)
Naturvetenskap (189)
Samhällsvetenskap (67)
Humaniora (47)
Teknik (14)
Lantbruksvetenskap (5)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy